These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 23607458)
1. The oxidative stress induced in vivo by Shiga toxin-2 contributes to the pathogenicity of haemolytic uraemic syndrome. Gomez SA; Abrey-Recalde MJ; Panek CA; Ferrarotti NF; Repetto MG; Mejías MP; Fernández GC; Vanzulli S; Isturiz MA; Palermo MS Clin Exp Immunol; 2013 Sep; 173(3):463-72. PubMed ID: 23607458 [TBL] [Abstract][Full Text] [Related]
2. Effect of antibiotics on cellular stress generated in Shiga toxin-producing Escherichia coli O157:H7 and non-O157 biofilms. Angel Villegas N; Baronetti J; Albesa I; Etcheverría A; Becerra MC; Padola NL; Paraje MG Toxicol In Vitro; 2015 Oct; 29(7):1692-700. PubMed ID: 26130220 [TBL] [Abstract][Full Text] [Related]
3. Pathogenic role of inflammatory response during Shiga toxin-associated hemolytic uremic syndrome (HUS). Exeni RA; Fernandez-Brando RJ; Santiago AP; Fiorentino GA; Exeni AM; Ramos MV; Palermo MS Pediatr Nephrol; 2018 Nov; 33(11):2057-2071. PubMed ID: 29372302 [TBL] [Abstract][Full Text] [Related]
4. Antibody response to lipopolysaccharides and recombinant proteins of Shiga toxin (STX)-producing Escherichia coli (STEC) in children with haemolytic uraemic syndrome in Poland. Rastawicki W; Śmietańska K; Rokosz-Chudziak N; Wołkowicz T Lett Appl Microbiol; 2020 Jun; 70(6):440-446. PubMed ID: 32270510 [TBL] [Abstract][Full Text] [Related]
5. Eculizumab in severe Shiga toxin-mediated haemolytic uraemic syndrome. Carroll M; Blake L; Sharma S BMJ Case Rep; 2024 Jan; 17(1):. PubMed ID: 38238162 [TBL] [Abstract][Full Text] [Related]
6. Heme as Possible Contributing Factor in the Evolvement of Shiga-Toxin Wijnsma KL; Veissi ST; de Wijs S; van der Velden T; Volokhina EB; Wagener FADTG; van de Kar NCAJ; van den Heuvel LP Front Immunol; 2020; 11():547406. PubMed ID: 33414780 [TBL] [Abstract][Full Text] [Related]
7. Shiga toxin-2 results in renal tubular injury but not thrombotic microangiopathy in heterozygous factor H-deficient mice. Paixão-Cavalcante D; Botto M; Cook HT; Pickering MC Clin Exp Immunol; 2009 Feb; 155(2):339-47. PubMed ID: 19040606 [TBL] [Abstract][Full Text] [Related]
8. Characterisation of the Escherichia coli strain associated with an outbreak of haemolytic uraemic syndrome in Germany, 2011: a microbiological study. Bielaszewska M; Mellmann A; Zhang W; Köck R; Fruth A; Bauwens A; Peters G; Karch H Lancet Infect Dis; 2011 Sep; 11(9):671-6. PubMed ID: 21703928 [TBL] [Abstract][Full Text] [Related]
9. Human mannose-binding lectin inhibitor prevents Shiga toxin-induced renal injury. Ozaki M; Kang Y; Tan YS; Pavlov VI; Liu B; Boyle DC; Kushak RI; Skjoedt MO; Grabowski EF; Taira Y; Stahl GL Kidney Int; 2016 Oct; 90(4):774-82. PubMed ID: 27378476 [TBL] [Abstract][Full Text] [Related]
10. Lack of specific binding of Shiga-like toxin (verocytotoxin) and non-specific interaction of Shiga-like toxin 2 antibody with human polymorphonuclear leucocytes. Geelen JM; van der Velden TJ; Te Loo DM; Boerman OC; van den Heuvel LP; Monnens LA Nephrol Dial Transplant; 2007 Mar; 22(3):749-55. PubMed ID: 17127697 [TBL] [Abstract][Full Text] [Related]
11. Relevance of neutrophils in the murine model of haemolytic uraemic syndrome: mechanisms involved in Shiga toxin type 2-induced neutrophilia. Fernandez GC; Lopez MF; Gomez SA; Ramos MV; Bentancor LV; Fernandez-Brando RJ; Landoni VI; Dran GI; Meiss R; Isturiz MA; Palermo MS Clin Exp Immunol; 2006 Oct; 146(1):76-84. PubMed ID: 16968401 [TBL] [Abstract][Full Text] [Related]
12. The Shiga toxin genotype rather than the amount of Shiga toxin or the cytotoxicity of Shiga toxin in vitro correlates with the appearance of the hemolytic uremic syndrome. Orth D; Grif K; Khan AB; Naim A; Dierich MP; Würzner R Diagn Microbiol Infect Dis; 2007 Nov; 59(3):235-42. PubMed ID: 17931818 [TBL] [Abstract][Full Text] [Related]
14. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. Morigi M; Galbusera M; Gastoldi S; Locatelli M; Buelli S; Pezzotta A; Pagani C; Noris M; Gobbi M; Stravalaci M; Rottoli D; Tedesco F; Remuzzi G; Zoja C J Immunol; 2011 Jul; 187(1):172-80. PubMed ID: 21642543 [TBL] [Abstract][Full Text] [Related]
15. Shiga toxin-induced haemolytic uraemic syndrome and the role of antibiotics: a global overview. Kakoullis L; Papachristodoulou E; Chra P; Panos G J Infect; 2019 Aug; 79(2):75-94. PubMed ID: 31150744 [TBL] [Abstract][Full Text] [Related]
16. Experimental In Vivo Models of Bacterial Shiga Toxin-Associated Hemolytic Uremic Syndrome. Jeong YJ; Park SK; Yoon SJ; Park YJ; Lee MS J Microbiol Biotechnol; 2018 Sep; 28(9):1413-1425. PubMed ID: 29926707 [TBL] [Abstract][Full Text] [Related]
17. Depletion of liver and splenic macrophages reduces the lethality of Shiga toxin-2 in a mouse model. Palermo MS; Alves Rosa MF; Van Rooijen N; Isturiz MA Clin Exp Immunol; 1999 Jun; 116(3):462-7. PubMed ID: 10361235 [TBL] [Abstract][Full Text] [Related]
18. Shiga toxin (Stx) type 2-induced increase in O-linked N-acetyl glucosamine protein modification: a new therapeutic target? Bova RA; Melton-Celsa A EMBO Mol Med; 2022 Jan; 14(1):e15389. PubMed ID: 34935281 [TBL] [Abstract][Full Text] [Related]